CN116098917A - 核苷类化合物在治疗冠状病毒感染性疾病中的用途 - Google Patents
核苷类化合物在治疗冠状病毒感染性疾病中的用途 Download PDFInfo
- Publication number
- CN116098917A CN116098917A CN202211442145.8A CN202211442145A CN116098917A CN 116098917 A CN116098917 A CN 116098917A CN 202211442145 A CN202211442145 A CN 202211442145A CN 116098917 A CN116098917 A CN 116098917A
- Authority
- CN
- China
- Prior art keywords
- acid
- formula
- alkyl
- compound
- infectious diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000001528 Coronaviridae Infections Diseases 0.000 title claims abstract description 16
- 208000019202 Orthocoronavirinae infectious disease Diseases 0.000 title claims abstract description 13
- -1 nucleoside compounds Chemical class 0.000 title claims description 7
- 239000002777 nucleoside Substances 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 21
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 8
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 claims description 4
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 4
- 229920002554 vinyl polymer Polymers 0.000 claims description 4
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 3
- 241000315672 SARS coronavirus Species 0.000 claims description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 claims description 2
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 claims description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 244000309467 Human Coronavirus Species 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- 235000011054 acetic acid Nutrition 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 238000013270 controlled release Methods 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 235000011087 fumaric acid Nutrition 0.000 claims description 2
- 239000000174 gluconic acid Substances 0.000 claims description 2
- 235000012208 gluconic acid Nutrition 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 229940045996 isethionic acid Drugs 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 229960002510 mandelic acid Drugs 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 claims description 2
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 claims description 2
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 235000019260 propionic acid Nutrition 0.000 claims description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 2
- 229960004889 salicylic acid Drugs 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 229960004365 benzoic acid Drugs 0.000 claims 1
- 229960004106 citric acid Drugs 0.000 claims 1
- 229960002598 fumaric acid Drugs 0.000 claims 1
- 229950006191 gluconic acid Drugs 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 229960000448 lactic acid Drugs 0.000 claims 1
- 229940098895 maleic acid Drugs 0.000 claims 1
- 229940099690 malic acid Drugs 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 229960001367 tartaric acid Drugs 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 abstract description 13
- 238000006243 chemical reaction Methods 0.000 abstract description 6
- 206010035664 Pneumonia Diseases 0.000 abstract description 4
- 241000700605 Viruses Species 0.000 abstract description 2
- 238000011330 nucleic acid test Methods 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 208000025721 COVID-19 Diseases 0.000 description 2
- 241001678559 COVID-19 virus Species 0.000 description 2
- 241000222336 Ganoderma Species 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- KTOLOIKYVCHRJW-XZMZPDFPSA-N 4-amino-1-[(2r,3s,4r,5r)-5-azido-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](F)[C@H](O)[C@](CO)(N=[N+]=[N-])O1 KTOLOIKYVCHRJW-XZMZPDFPSA-N 0.000 description 1
- 229940124321 AIDS medicine Drugs 0.000 description 1
- 208000031636 Body Temperature Changes Diseases 0.000 description 1
- 241000502280 Clitocybe Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 210000003029 clitoris Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000011329 viral nucleic acid test Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
式(I)所示的化合物或其药学上可接受的盐在制备预防或治疗冠状病毒感染性疾病的药物中的用途，所述式(I)化合物用于治疗新冠状病毒肺炎病人，在病毒核酸试验转阴率、转阴疗程、治愈出院时间都显示明显优势。
Description
技术领域
本发明涉及核苷类化合物新的抗病毒用途。
背景技术
冠状病毒(Coronavirus,CoV)是一类有包膜的正向单链RNA病毒，在人类、其他哺乳动物和鸟类中广泛传播，并可导致呼吸道、肠道、肝脏和神经系统等疾病。目前已知有七种CoV可导致人类疾病，其中四种CoV-229E、-OC43、-NL63和-HKU1在人群中流行，并通常引起普通感冒症状。而其他三种SARS-CoV、MERS-CoV和新冠状病毒(2019-nCoV，或称COVID-19)都具有发病快、传染性强和致死率高的严重危害性。因此，快速研发直接抗病毒药物，治疗新冠状病毒感染，十分迫切。
发明内容
化合物1作为抗艾滋病药物已经完成II期临床试验，安全性良好。
发明人在新冠状病毒感染的MRC-5细胞内，测定了化合物1的体外抗病毒活性。结果表明，化合物1只有微弱的抑制新冠状病毒的活性(EC50为25μM)。
然而，发明人直接用式(1)化合物进行研究性临床试验，惊奇地发现，较对照性常规治疗，用式(1)化合物治疗新冠状病毒肺炎病人，在病毒核酸试验转阴率、转阴疗程、治愈出院时间都显示明显优势。发明人认为，化合物1没有显示明显抑制病毒作用，可能与其在体外中不能有效地磷酸酯化有关。
鉴于此，本文中一方面，提供式(I)所示的化合物、或其药学上可接受的盐在制备预防或治疗冠状病毒感染性疾病的药物中的用途，另一方面，本文中提供一种预防或治疗冠状病毒感染性疾病的方法，包括向有此需要的患者给予治疗或预防有效量的式(I)化合物或其药学上可接受的盐，
其中式(I)结构式如下：
式(I)中，
R1为OR1基团可以在体内代谢释放出羟基，或者形成O-磷酸基的任何基团；OR1优选为酯基，R1优选为H、R5-CO-、或
其中Ar是苯基和取代苯基，萘基和取代萘基，所述取代基选自C1-6烷基、F、Cl、Br、I、CN、N3、OH、NH2、OR5、NHR5；
R2选自:H、叠氮基、C1-C6烷基(例如甲基、乙基)、C1-C6烷氧基(例如甲氧基、乙氧基)、C2-C6炔基(例如乙炔基)、C2-C6烯基(例如乙烯基)、卤代C1-C6烷基(例如2-氯乙基、2-氟乙基、三氟乙基)；
R3选自H、任选被取代的R-CO-、任选被取代的R-O(C＝O)-、和任选被取代的RNH-CO-，其中R选自C1-C6烷基(例如甲基、乙基、丙基、异丙基、丁基、异丁基、戊基、异戊基等)；其中，取代基选自C1-C6烷基、卤素(如F、Cl)、CN、N3、和OR5。
R4选自H、OH、卤素(例如F)、C1-C6烷基(例如甲基，乙基)、C1-C6烷氧基(例如甲氧基，乙氧基)；
B选自：
其中，X1选自-OH、-NH2、R5CONH-、R5COO-、R5O(C＝O)NH-；
X2选自-OH、-SH、-NH2、R5COO-、R5COS-、R5CONH2-、R5O(C＝O)NH-；X3选自H、F、-OH和-NH2；
Y选自CH和N；
Z为H、-OH或F；
R5选自H、C1-C6烷基(例如甲基、乙基、丙基、异丙基)、C2-C6炔基(例如乙炔基)、C2-C6烯基(例如乙烯基)、卤代C1-C6烷基(例如2-氯乙基、2-氟乙基、三氟乙基)、任选被C1-6烷基、C1-6烷氧基、CN、N3、OH、NH2、卤素(例如F、Cl、Br、I)取代的苯基、任选被C1-6烷基、C1-6烷氧基、CN、N3、OH、NH2、卤素(例如F、Cl、Br、I)取代的萘基。
优先如下化合物或其药学上可接受的盐：
式(I)化合物的药学上可接受的盐包括，但不限于，例如式(I)化合物与以下酸形成的盐：盐酸、氢溴酸、氨基磺酸、硫酸、磷酸、硝酸、甲酸、乙酸、丙酸、草酸、乙醇酸、丙二酸、苯甲酸、乳酸、葡糖酸、柠檬酸、酒石酸、琥珀酸、富马酸、马来酸、杏仁酸、苹果酸、甲磺酸、乙磺酸、羟乙基磺酸、苯磺酸、对甲苯磺酸、萘磺酸、萘二磺酸、樟脑磺酸、抗坏血酸棕榈酸、水杨酸、磺基水杨酸、2-羟基-3-萘甲酸、邻苯二甲酸、赖氨酸、精氨酸、谷氨酸、甘氨酸、丝氨酸、苏氨酸、丙氨酸、异亮氨酸、亮氨酸等。
式(I)化合物可通过商业渠道购买或者已知的方法制得。
本文中冠状病毒感染性疾病，是由冠状病毒科病毒感染所引发的疾病，包括感染人或其他动物所引起的疾病。特别是人冠状病毒感染人类所引发的疾病，包括但不限于CoV-229E、-OC43、-NL63、-HKU1、SARS-CoV、MERS-CoV和新冠状病毒(2019-nCoV，或称COVID-19)感染引起的疾病。
式(I)化合物的治疗和预防冠状病毒感染性疾病的有效量可由本领域技术人员根据本文提供的信息确定。例如，成年人用量可以为1-500mg/天，可选为1-50mg/天，可选为1-20mg/天；可选为1-10mg/天，可选为5mg/天。可以单次或分多次给药。
给药方式可以为口服或者胃肠外给药。可以是速释剂型，也可以是缓释剂型、控释剂型。具体剂型可是本领域的各种常规剂型。例如，口服制剂可以列举片剂、硬或软胶囊剂、水性或油性混悬剂、颗粒剂、乳剂、糖浆剂或酏剂等。注射剂可以列举注射液、粉针剂等。
具体实施方式
以下对本发明的具体实施方式进行详细说明。应当理解的是，此处所描述的具体实施方式仅用于示例性地对本发明进行说明，并不用于限制本发明。
试验例
临床试验验证化合物用于治疗新冠状病毒(COVID-19)肺炎的有效性和安全性。
选择20例通过核酸试剂测定确诊新冠状病毒感染的患者，分为阿兹夫定(化合物1)组和克力芝对照组，每组10例。阿兹夫定组治疗方案：每天服用5毫克(口服，5片，每片1毫克)；克力芝对照组治疗方案：克力芝(口服，2片/日，250mg/片)+阿比多尔片(口服200mg/次，3次/日)+干扰素(500万U，每日两次雾化吸入)。测定核酸变化，体温变化，观察各种症状。
结果如下表所示。
临床试验结果表明，10例新冠状病毒感染患者中，阿兹夫定组全部患者核酸检测转阴，其中7例第8天内出院。
上述临床试验结果表明，化合物1治疗新冠病毒肺炎在病人核酸转阴率、转阴疗程、治愈率和治愈疗程几个指标都显示显著临床治疗优势。
其中一例使用克力芝支持治疗20多天仍不能转阴的病人，采用化合物1治疗后3天转阴。治疗中，没有发现任何药物有关的毒副作用。
Claims (5)
1.式(I)所示的化合物或其药学上可接受的盐在制备预防或治疗冠状病毒感染性疾病的药物中的用途，
式(I)中，
R1为H、R5-CO-、或
其中Ar为苯基、取代苯基、萘基或取代萘基，其中取代基选自C1-6烷基、F、Cl、Br、I、CN、N3、OH、NH2、OR5、NHR5；
R2为:H、叠氮基、C1-C6烷基(例如甲基、乙基)、C1-C6烷氧基(如甲氧基、乙氧基)、C2-C6炔基(例如乙炔基)、C2-C6烯基(例如乙烯基)、或者卤代C1-C6烷基(例如2-氯乙基、2-氟乙基、三氟乙基)；
R3为H、任选被取代的R-CO-、任选被取代的R-O(C＝O)-、或任选被取代的RNH-CO-，其中R为C1-C6烷基(例如甲基、乙基、丙基、异丙基、丁基、异丁基、戊基、异戊基等)，其中，取代基选自C1-C6烷基、卤素(如F、Cl)、CN、N3、和OR5；
R4为H、OH、卤素(例如F)、C1-C6烷基(例如甲基，乙基)、或C1-C6烷氧基(例如甲氧基，乙氧基)；
B选自：
其中，X1为-OH、-NH2、R5CONH-、R5COO-或R5O(C＝O)NH-；
X2为OH、SH、NH2、R5COO-、R5COS-、R5CONH2-、或R5O(C＝O)NH-；X3为H、F、OH或NH2；
Y为CH或N；
Z为H、OH或F；
R5选自H、C1-C6烷基(例如甲基、乙基、丙基、异丙基)、C2-C6炔基(例如乙炔基)、C2-C6烯基(例如乙烯基)、卤代C1-C6烷基(例如2-氯乙基、2-氟乙基、三氟乙基)、任选被C1-6烷基、C1-6烷氧基、CN、N3、OH、NH2、卤素(例如F、Cl、Br、I)取代的苯基、任选被C1-6烷基、C1-6烷氧基、CN、N3、OH、NH2、卤素(例如F、Cl、Br、I)取代的萘基。
2.根据权利要求1所述的式(I)所示化合物或其药学上可接受的盐在制备预防或治疗冠状病毒感染性疾病的药物中的用途，其中式(I)所示化合物为下列化合物：
或者
。
3.根据权利要求1或2所述的式(I)所示化合物或其药学上可接受的盐在制备预防或治疗冠状病毒感染性疾病的药物中的用途，其中式(I)化合物的药学上可接受的盐包括式(I)化合物与以下酸形成的盐：盐酸、氢溴酸、氨基磺酸、硫酸、磷酸、硝酸、甲酸、乙酸、丙酸、草酸、乙醇酸、丙二酸、苯甲酸、乳酸、葡糖酸、柠檬酸、酒石酸、琥珀酸、富马酸、马来酸、杏仁酸、苹果酸、甲磺酸、乙磺酸、羟乙基磺酸、苯磺酸、对甲苯磺酸、萘磺酸、萘二磺酸、樟脑磺酸、抗坏血酸棕榈酸、水杨酸、磺基水杨酸、2-羟基-3-萘甲酸、邻苯二甲酸、赖氨酸、精氨酸、谷氨酸、甘氨酸、丝氨酸、苏氨酸、丙氨酸、异亮氨酸或亮氨酸。
4.根据权利要求1-3任一项所述的式(I)所示化合物或其药学上可接受的盐在制备预防或治疗冠状病毒感染性疾病的药物中的用途，其中所述冠状病毒感染性疾病是由冠状病毒科病毒感染所引发的疾病，包括感染人或其他动物所引起的疾病，尤其是人冠状病毒感染人类所引发的疾病，例如，CoV-229E、-OC43、-NL63、-HKU1、SARS-CoV、MERS-CoV或COVID-19感染引起的疾病。
5.根据权利要求1-3任一项所述的式(I)所示化合物或其药学上可接受的盐在制备预防或治疗冠状病毒感染性疾病的药物中的用途，其中所述药物剂型为速释剂型、缓释剂型、或控释剂型，例如片剂、硬、软胶囊剂、水性或油性混悬剂、颗粒剂、乳剂、糖浆剂、酏剂、注射液、或粉针剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211442145.8A CN116098917A (zh) | 2020-02-27 | 2020-02-27 | 核苷类化合物在治疗冠状病毒感染性疾病中的用途 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211442145.8A CN116098917A (zh) | 2020-02-27 | 2020-02-27 | 核苷类化合物在治疗冠状病毒感染性疾病中的用途 |
| CN202010125799.2A CN113304166B (zh) | 2020-02-27 | 2020-02-27 | 核苷类化合物在制备治疗冠状病毒感染性疾病的药物中的用途 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010125799.2A Division CN113304166B (zh) | 2020-02-27 | 2020-02-27 | 核苷类化合物在制备治疗冠状病毒感染性疾病的药物中的用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116098917A true CN116098917A (zh) | 2023-05-12 |
Family
ID=77370412
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211442145.8A Pending CN116098917A (zh) | 2020-02-27 | 2020-02-27 | 核苷类化合物在治疗冠状病毒感染性疾病中的用途 |
| CN202010125799.2A Active CN113304166B (zh) | 2020-02-27 | 2020-02-27 | 核苷类化合物在制备治疗冠状病毒感染性疾病的药物中的用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010125799.2A Active CN113304166B (zh) | 2020-02-27 | 2020-02-27 | 核苷类化合物在制备治疗冠状病毒感染性疾病的药物中的用途 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230277576A1 (zh) |
| EP (1) | EP4112050A4 (zh) |
| JP (1) | JP7522845B2 (zh) |
| KR (1) | KR20220146496A (zh) |
| CN (2) | CN116098917A (zh) |
| AU (1) | AU2021228008B2 (zh) |
| BR (1) | BR112022017209A2 (zh) |
| CA (1) | CA3167927A1 (zh) |
| IL (1) | IL295840A (zh) |
| MA (1) | MA57574A1 (zh) |
| MX (1) | MX2022010248A (zh) |
| WO (1) | WO2021169861A1 (zh) |
| ZA (1) | ZA202210636B (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114288313B (zh) * | 2022-02-18 | 2023-07-04 | 常晓宇 | 嘧啶核苷类药物在制备预防或治疗冠状病毒感染性疾病药物中的用途 |
| CN114504578A (zh) * | 2022-03-03 | 2022-05-17 | 苏州旺山旺水生物医药有限公司 | 治疗、预防由病毒感染引起的相关疾病的药物及其用途 |
| CN117982522A (zh) * | 2022-11-02 | 2024-05-07 | 河南真实生物科技有限公司 | 核苷类化合物的制药用途 |
| WO2024103016A1 (en) * | 2022-11-11 | 2024-05-16 | Rome Therapeutics, Inc. | 4'-halomethyl-cytidine phosphoramidates and related compounds and their use in treating medical conditions |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003018030A1 (en) * | 2001-08-24 | 2003-03-06 | Koronis Pharmaceuticals, Inc. | Mutagenic nucleoside analogs for the treatment of viral disease |
| US20040259934A1 (en) * | 2003-05-01 | 2004-12-23 | Olsen David B. | Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds |
| CN100398555C (zh) * | 2003-05-06 | 2008-07-02 | 西托维亚公司 | 冠状病毒和sars-cov的蛋白酶抑制剂及其应用 |
| WO2005020885A2 (en) * | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| CN1237185C (zh) * | 2003-06-04 | 2006-01-18 | 中国科学院上海药物研究所 | Sars冠状病毒3cl蛋白酶三维结构模型与抗sars药物 |
| MX369307B (es) * | 2016-08-19 | 2019-11-05 | Gilead Sciences Inc | Compuestos terapeuticos utiles para tratamiento profilactico o terapeutico de infeccion por virus de inmunodeficiencia humana. |
| WO2019123338A1 (en) * | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'2' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| AU2019221568B2 (en) * | 2018-02-15 | 2021-04-22 | Gilead Sciences, Inc. | Pyridine derivatives and their use for treating HIV infection |
| TWI829205B (zh) * | 2018-07-30 | 2024-01-11 | 美商基利科學股份有限公司 | 抗hiv化合物 |
-
2020
- 2020-02-27 CN CN202211442145.8A patent/CN116098917A/zh active Pending
- 2020-02-27 CN CN202010125799.2A patent/CN113304166B/zh active Active
-
2021
- 2021-02-20 MX MX2022010248A patent/MX2022010248A/es unknown
- 2021-02-20 MA MA57574A patent/MA57574A1/fr unknown
- 2021-02-20 KR KR1020227030688A patent/KR20220146496A/ko not_active Application Discontinuation
- 2021-02-20 US US17/905,142 patent/US20230277576A1/en active Pending
- 2021-02-20 BR BR112022017209A patent/BR112022017209A2/pt unknown
- 2021-02-20 AU AU2021228008A patent/AU2021228008B2/en active Active
- 2021-02-20 IL IL295840A patent/IL295840A/en unknown
- 2021-02-20 WO PCT/CN2021/077010 patent/WO2021169861A1/zh active Application Filing
- 2021-02-20 JP JP2022551819A patent/JP7522845B2/ja active Active
- 2021-02-20 CA CA3167927A patent/CA3167927A1/en active Pending
- 2021-02-20 EP EP21760199.6A patent/EP4112050A4/en active Pending
-
2022
- 2022-09-26 ZA ZA2022/10636A patent/ZA202210636B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN113304166A (zh) | 2021-08-27 |
| MX2022010248A (es) | 2022-10-10 |
| EP4112050A4 (en) | 2024-03-20 |
| WO2021169861A1 (zh) | 2021-09-02 |
| JP7522845B2 (ja) | 2024-07-25 |
| CA3167927A1 (en) | 2021-09-02 |
| IL295840A (en) | 2022-10-01 |
| EP4112050A1 (en) | 2023-01-04 |
| KR20220146496A (ko) | 2022-11-01 |
| ZA202210636B (en) | 2024-01-31 |
| BR112022017209A2 (pt) | 2022-10-11 |
| US20230277576A1 (en) | 2023-09-07 |
| JP2023516628A (ja) | 2023-04-20 |
| MA57574A1 (fr) | 2023-11-30 |
| CN113304166B (zh) | 2022-10-14 |
| AU2021228008B2 (en) | 2024-08-08 |
| AU2021228008A1 (en) | 2022-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116098917A (zh) | 核苷类化合物在治疗冠状病毒感染性疾病中的用途 | |
| RU2700415C1 (ru) | Ингибиторы репликации вирусов гриппа | |
| US20180185404A1 (en) | Compositions and methods for the treatment of viral infection | |
| AU770495B2 (en) | Medicinal compositions for preventing or treating viral myocarditis | |
| EP3900717A1 (en) | Vidofludimus for use in the treatment or prevention of viral diseases | |
| JP2020196704A (ja) | インフルエンザウイルス感染症またはコロナウイルス感染症の予防および／または治療剤 | |
| CN113773275A (zh) | 一种抗病毒化合物及其制备方法 | |
| CN112121044A (zh) | 氨来占诺用于制备抗肝炎病毒药物的用途 | |
| JP2010528053A (ja) | インフルエンザ感染症を治療するための物質および方法 | |
| EP3934653B1 (en) | Azelastine as antiviral treatment | |
| EP4126034A1 (en) | Method of treating coronavirus infection by administration of ethyl mercury or thiol derivative thereof | |
| CN112691094B (zh) | 防治病毒的新型化合物及其应用 | |
| CN116687932B (zh) | ((3-氨甲酰-5-氟吡嗪-2-基)氧基)甲基异丁酸酯的医药用途 | |
| AU2010317727A1 (en) | Treatment of microbial infections | |
| RU2824607C2 (ru) | 2-(имидазол-4-ил)-этанамид пентандиовой-1,5 кислоты или его фармацевтически приемлемая соль для лечения covid-19 и ее симптомов | |
| WO2023040990A1 (zh) | 治疗冠状病毒感染的新联用药物、药物组合物及其用途 | |
| CN117982522A (zh) | 核苷类化合物的制药用途 | |
| CN110721312B (zh) | 用于治疗小儿呼吸道感染的药物组合物及其相关制剂 | |
| CN113398120A (zh) | 阿比多尔在制备预防或治疗SARS-CoV-2病毒所致疾病的药物中的用途 | |
| JP2003155230A (ja) | 抗インフルエンザ薬 | |
| WO2021233956A1 (en) | Ezetimibe for treating enveloped virus infections | |
| CN117503776A (zh) | 一种药物组合物及其用途 | |
| CN117653637A (zh) | 恩替卡韦的新用途 | |
| CN114225005A (zh) | 一种可有效抑制HIV、HBV、H1N1、H3N2和nCoV的复合口服糖浆 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |